Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for treating infection and method

A composition and virus infection technology, applied in the direction of drug combination, pharmaceutical formula, and resistance to vector-borne diseases, etc., can solve the problem of not clearing virions

Inactive Publication Date: 2010-09-22
帕特里克·T·普伦德加斯特
View PDF5 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, they do not clear virions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for treating infection and method
  • Composition for treating infection and method
  • Composition for treating infection and method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0159] Example 1: Antiviral activity of triterpene glycoside mogroside V on BVDV

[0160] Materials and methods

[0161] The antiviral activity of mogroside V was tested against bovine viral diarrhea virus (BVDV), strain NADL. BVDV is a flavivirus of the same family as the human hepatitis C virus. Hepatitis C cannot grow in tissue culture, so BVDV was used as a model virus due to the structural similarities between the two viruses. Titrate the virus and determine the 10% of stock virus -4 Dilute to achieve a suitable inoculum for antiviral assays.

[0162] Mogroside V can be stored at room temperature and is water soluble. Mogroside V was independently tested over a wide concentration range (6.25-3600 μg / mL). Mogroside V was tested in two experiments, one at 100, 50, 25, 12.5 and 6.25 μg / mL and the other at 3600, 1200, 400, 133.3 μg / mL and 44.4 μg / mL.

[0163] Bos Taurus (BT) turbinate cells were used as host cells for the virus. After plating the cells and allowing o...

Embodiment 2

[0183] Example 2: Triterpene glycoside mogroside V on BVDV when combined with fluvastatin antiviral activity

[0184] Materials and methods

[0185] Materials and methods were similar to those outlined in Example 1. Fluvastatin must be stored between 0°C and 5°C and be water soluble. Mogroside V and fluvastatin were jointly tested, in which mogroside V had two concentrations: an effective dose (100 μg / mL) and a dose below its effective range (6 μg / mL), while fluvastatin had Within 5 doses (0.313, 0.625, 1.25, 2.5, and 5.0 μg / mL).

[0186] result

[0187] Studies have shown that fluvastatin extends the lower limit of the effectiveness of mogroside V. Especially, in the case of using 6 μg / mL mogroside V, the inhibition index of fluvastatin at 5 μg / mL and 0.3125 μg / mL was greatly improved compared with that of fluvastatin alone ( figure 2 ).

[0188] Table 3 shows the percentage and inhibition index of the negative control of various concentrations of mogroside V and...

Embodiment 3

[0197] Example 3. Antiviral activity of mogroside IV against BVDV

[0198] Materials and methods

[0199] The antiviral potency and cytotoxicity of five test compounds against bovine viral diarrhea virus (BVDV) were evaluated. BVDV is a flavivirus belonging to the same family as the human hepatitis C virus. Hepatitis C virus cannot grow in tissue culture, therefore, BVDV was used as a model virus due to the structural similarities between these two viruses. The five test compounds were evaluated in a CPE (virus-induced cytopathic effect)-inhibition assay using the BVDV strain NADL in Madin-Darby bovine kidney (Madin-Darby bovine kidney; MDBK) cells.

[0200] drug preparation

[0201] The five test compounds were supplied as dry powders and dissolved in molecular quality sterile water to obtain 20 mg / mL stock solutions listed in Table 4. All compounds were evaluated in six half log serial dilutions with a high test concentration of 100 μg / mL. Recombinant interferon a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a composition containing at least one triterpene glucoside or an analogue, a metabolite, a precursor, a derivative, a medicinal active salt or a pre-drug thereof and application of the composition in preparing medicaments for treating and / or preventing viral infection. The invention also provides application of a joint composition consisting of the composition and a composition containing fluvastatin or an analogue, a metabolite, a derivative, a medicinal active salt, a precursor or a pre-drug thereof in preparing medicaments for treating and / or preventing viral infection. The composition and the method can be further used for preventing infection of subject patients or the attack and development of other disease symptoms related to viral infection of hepatitis C, such as liver cirrhosis, decompensatory liver diseases and / or hepatocellular carcinoma.

Description

technical field [0001] The present invention relates to compositions and methods useful for the prevention and / or treatment of viral infections, especially hepatitis C and HIV. Background technique [0002] Hepatitis C (HCV), formerly known as blood-borne non-A, non-B hepatitis virus (NANBV), is an infectious disease distinct from other forms of virus-associated liver disease, including those caused by hepatitis A virus (HAV), hepatitis B virus (HBV), and delta hepatitis virus (HDV). Hepatitis C was first detected in individuals receiving blood transfusions. Chronic infection with hepatitis C virus is an insidious and slowly progressive disease that has a marked impact on quality of life. It can eventually lead to cirrhosis, decompensated liver disease and / or hepatocellular carcinoma. [0003] Interferon-alpha monotherapy is commonly used to treat chronic hepatitis C infection. However, this treatment is not always effective and sometimes leads to intolerable side effect...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/704A61K31/405A61P31/12A61P31/18A61P31/20A61P31/14A61P1/16
CPCY02A50/30
Inventor 帕特里克·T·普伦德加斯特
Owner 帕特里克·T·普伦德加斯特
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com